What is Immunome's net income?

Immunome (IMNM) reported net income of -$53.84M in Q1 2026.

How has Immunome's net income changed year-over-year?

Immunome's net income decreased by 29.3% year-over-year, from -$41.64M to -$53.84M.

What is the long-term trend for Immunome's net income?

Over 4 years (2021 to 2025), Immunome's net income has grown at a 71.2% compound annual growth rate (CAGR), from -$24.71M to -$212.39M.

What does net income mean?

The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Immunome IMNM Net Income

Net Income at other companies

PfizerPFE

$2.69B-9.4%

Arcus BiosciencesRCUS

-$128M-14.3%

Nuvation BioNUVB

$5.4M+110%

SELLAS Life Sciences Group, Inc.SLS

-$8.41M-44.6%

IDEAYA Biosciences, Inc.IDYA

-$98.54M-36.5%

ImmunityBio, Inc.IBRX

-$632.78M-388%

Segments

By segment

See full

Single Reportable-$53.84M-29.3%

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's net income?: Immunome (IMNM) reported net income of -$53.84M in Q1 2026.
How has Immunome's net income changed year-over-year?: Immunome's net income decreased by 29.3% year-over-year, from -$41.64M to -$53.84M.
What is the long-term trend for Immunome's net income?: Over 4 years (2021 to 2025), Immunome's net income has grown at a 71.2% compound annual growth rate (CAGR), from -$24.71M to -$212.39M.
What does net income mean?: The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.